Sulla

Sulla Therapeutics was a biotechnology company dedicated to the discovery and development of small molecule therapeutics targeting transcription factors. Founded by world-renowned scientists from the Whitehead Institute and Dana-Farber Cancer Institute, the company focused on 'undruggable' targets involved in gene regulation and transcriptional addiction in cancer. Sulla operated primarily in stealth mode, leveraging cutting-edge research into super-enhancers and transcriptional condensates. In 2020, the company was acquired by Eli Lilly and Company to bolster its oncology research portfolio. The integration of Sulla's expertise allowed Lilly to expand its capabilities in modulating gene expression for therapeutic benefit.